Martyna Filipska

Barcelona Biomedical Research Park
Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

TACItness MZ B cell maturation.

TACItness MZ B cell maturation.

Journal: The Journal of experimental medicine

Published: May 05, 2026

IgD from atypical-like memory B cells and plasma cells targets commensal and environmental antigens.

IgD from atypical-like memory B cells and plasma cells targets commensal and environmental antigens.

Journal: The Journal of experimental medicine

Published: August 26, 2025

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer.

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer.

Journal: Pharmaceutics

Published: August 08, 2022

Impact of the mucosal milieu on antibody responses to allergens.

Impact of the mucosal milieu on antibody responses to allergens.

Journal: The Journal of allergy and clinical immunology

Published: June 02, 2022

Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.

Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.

Journal: Molecular oncology

Published: August 16, 2021

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Journal: Molecular oncology

Published: December 29, 2020

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

Journal: Frontiers in oncology

Published: June 04, 2020

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.

Journal: Annals of translational medicine

Published: January 14, 2020

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.

Journal: Expert review of respiratory medicine

Published: August 15, 2019

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.

Journal: Expert opinion on biological therapy

Published: February 15, 2019

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).

Journal: International journal of biological sciences

Published: January 21, 2019

Combining plasma-based biosources to predict treatment response in NSCLC patients.

Combining plasma-based biosources to predict treatment response in NSCLC patients.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 01, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026